Click here to learn more about how the Afirma^® Thyroid FNA Analysis is reducing unnecessary thyroid surgeries and lowering healthcare costs.

Veracyte is pioneering the emerging field of molecular cytology by focusing on disease states that have high rates of ambiguous diagnostic test results. More on our pipeline.

Veracyte Announces UnitedHealthcare Coverage Policy For the Afirma Gene Expression Classifier
(Mar 8, 2013)

Veracyte Announces That New Guidelines Include Molecular Testing for Indeterminate Thyroid Nodules To Reduce Unnecessary Surgeries  
(Jan 7, 2013)